Skip to content

US · IVVD · BIOTECHNOLOGY

Invivyd, Inc. (IVVD) intrinsic value and stock valuation

$0.41as of 2026-11-21 · Mkt cap 178.06M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Invivyd, Inc. DCF and intrinsic value

InvestorsCraft values IVVD with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from IVVD’s statements →

Invivyd, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology New Haven, CT 06510 invivyd.com

How the business is doing

Fiscal 2020–2025, USD

Revenue
$53.4M
20202025
Net income
-$-52.49M
20202025
Free cash flow
-$-58.29M
20202025
Total equity
$241.5M
20202025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2020–2025, USD
20252024202320222021
Revenue$53.4M$25.4M$0.00$0.00$0.00
Operating income-$-55.56M-$-176.88M-$-212.76M-$-248.03M-$-226.91M
Net income-$-52.49M-$-169.93M-$-198.64M-$-241.32M-$-226.79M
EPSd-$-304.8K-$-1.43M-$-1.81M-$-2.23M-$-2.05M
Operating cash flow-$-58.13M-$-170.49M-$-173.16M-$-219.99M-$-184.74M
Capital expenditure-$-150K-$-140K-$-610K-$-1.71M-$-80K
Free cash flow-$-58.29M-$-170.63M-$-173.78M-$-221.69M-$-184.82M
Total assets$276.9M$129.5M$229.2M$383.2M$620.1M
Total debt$2.49M$1.3M$2.17M$3.72M$0.00
Net debt-$-224.19M-$-68.05M-$-198.48M-$-88.35M-$-542.22M
Total equity$241.5M$67.5M$177.5M$356M$558M
Cash and short-term investments$226.7M$69.4M$200.6M$372M$591.4M
Income statement
20252024202320222021
Revenue$53.4M$25.4M$0.00$0.00$0.00
Cost of revenue$3.75M$1.62M$0.00$0.00$0.00
Gross profit$49.7M$23.8M$0.00$0.00$0.00
Research and development expenses$38.3M$137.3M$158.7M$179.2M$182.9M
Selling, general and administrative expenses$66.9M$63.4M$49.1M$47M$36.5M
Other expenses$0.00$0.00$4.97M$21.8M$7.5M
Operating expenses$105.2M$200.6M$212.8M$248M$226.9M
Cost and expenses$109M$202.3M$212.8M$248M$226.9M
Interest income$0.00$6.95M$0.00$6.71M$0.00
Interest expense$0.00$0.00$0.00$43.1M$0.00
Depreciation and amortization$2.11M$3.11M$2.03M$460K$0.00
Ebitda-$-50.38M-$-166.81M-$-205.75M-$-225.8M-$-219.41M
Operating income-$-55.56M-$-176.88M-$-212.76M-$-248.03M-$-226.91M
Total other income/expenses, net$3.07M$6.95M$14.1M$6.71M$120K
Income before tax-$-52.49M-$-169.93M-$-198.64M-$-241.32M-$-226.79M
Income tax expense$0.00$0.00$0.00$0.00$0.00
Net income-$-52.49M-$-169.93M-$-198.64M-$-241.32M-$-226.79M
Weighted average shares outstanding$172.2M$118.6M$109.5M$108.3M$110.8M
Weighted average diluted shares outstanding$172.2M$118.6M$109.5M$108.3M$110.8M
Balance sheet
20252024202320222021
Cash and short-term investments$226.7M$69.4M$200.6M$372M$591.4M
Net receivables$14.6M$11.2M$930K$380K$230K
Inventory$25.5M$0.00$0.00$0.00$0.00
Total current assets$247.5M$100.7M$224.9M$376.9M$616.7M
Property, plant and equipment, net$3.81M$2.89M$4.12M$6.06M$80K
Goodwill and intangible assets$0.00$0.00$0.00$0.00$0.00
Long-term investments$0.00$0.00$0.00$0.00$0.00
Total non-current assets$29.4M$28.8M$4.3M$6.25M$3.38M
Total assets$276.9M$129.5M$229.2M$383.2M$620.1M
Accounts payable$13.7M$10.5M$7.95M$1.52M$5.78M
Short-term debt$1.31M$1.3M$1.44M$1.56M$0.00
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$34.2M$62M$50.3M$25M$62.1M
Long-term debt$1.18M$0.00$720K$2.17M$0.00
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$1.18M-$0.00$1.42M$2.17M$10K
Capital lease obligations$2.49M$1.3M$2.17M$3.72M$0.00
Total liabilities$35.3M$62M$51.7M$27.2M$62.1M
Common stock$30K$10K$10K$10K$10K
Retained earnings-$-954.48M-$-901.99M-$-732.07M-$-533.43M-$-292.11M
Accumulated other comprehensive income (loss)-$-40K-$-10K-$-10K-$-270K-$-10K
Total equity$241.5M$67.5M$177.5M$356M$558M
Total investments$0.00$0.00$0.00$279.9M$49.2M
Total debt$2.49M$1.3M$2.17M$3.72M$0.00
Net debt-$-224.19M-$-68.05M-$-198.48M-$-88.35M-$-542.22M
Cash flow statement
20252024202320222021
Net income-$-52.49M-$-169.93M-$-198.64M-$-241.32M-$-226.79M
Depreciation and amortization$2.11M$3.11M$2.03M$460K$0.00
Stock-based compensation$11.6M$19.8M$18.7M$21.7M$17.8M
Change in working capital-$-19.69M-$-23.47M$5.89M-$-16.13M$22.8M
Accounts receivable-$-3.34M-$-10.91M$0.00$0.00$0.00
Inventory-$-370K-$-24.89M$0.00$0.00$0.00
Accounts payable$3.21M$2.42M$6.47M-$-4.3M-$-2.37M
Net cash provided by operating activities-$-58.13M-$-170.49M-$-173.16M-$-219.99M-$-184.74M
Investments in property, plant and equipment-$-150K-$-140K-$-610K-$-1.71M-$-80K
Acquisitions, net$0.00$0.00$0.00$0.00$0.00
Net cash used for investing activities-$-150K-$-140K$280.7M-$-230.67M-$-50.71M
Common stock issued$215.6M$39.3M$1.2M$510K$330.9M
Common stock repurchased$0.00$0.00-$0.00-$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$215.6M$39.3M$1.04M$510K$662.7M
Net change in cash$157.3M-$-131.29M$108.6M-$-450.15M$427.2M
Cash at end of period$226.7M$69.4M$200.6M$92.1M$542.2M
Operating cash flow-$-58.13M-$-170.49M-$-173.16M-$-219.99M-$-184.74M
Capital expenditure-$-150K-$-140K-$-610K-$-1.71M-$-80K
Free cash flow-$-58.29M-$-170.63M-$-173.78M-$-221.69M-$-184.82M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Invivyd, Inc.

        Adagio Therapeutics, Inc., a biopharmaceutical firm in its clinical development phase, operates within the United States, specializing in the discovery, progression, and marketing of antibody-derived solutions for infectious diseases. The company's leading drug candidate, ADG20 (adintrevimab), is a neutralizing antibody currently undergoing Phase 3 clinical investigation for both the management and prevention of coronavirus disease. Adagio Therapeutics maintains collaborative agreements with Adimab, LLC to facilitate the identification and enhancement of its exclusive antibodies. Furthermore, it partners with the Scripps Research Institute to conduct studies aimed at uncovering potential vaccine solutions for the prophylaxis, detection, or therapy of influenza or beta coronaviruses. Incorporated in 2020, the company's base of operations is in Waltham, Massachusetts.

        CEO
        William E. Duke Jr.
        Employees
        122
        Beta
        0.67

        Explore

        Frequently asked questions

        What is the intrinsic value of Invivyd, Inc. (IVVD)?

        InvestorsCraft does not currently publish an intrinsic value for IVVD. How the IC value is calculated.

        Is IVVD undervalued?

        InvestorsCraft does not publish an undervaluation signal for IVVD at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.